Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin

被引:21
作者
Zhou, Mingyan [1 ]
Xu, Aimin [1 ,2 ]
Lam, Karen S. L. [1 ,2 ]
Tam, Paul K. H. [3 ]
Che, Chi-Ming [4 ]
Chan, Lawrence [5 ,6 ]
Lee, In-Kyu [7 ]
Wu, Donghai [8 ]
Wang, Yu [1 ,3 ,8 ]
机构
[1] Univ Hong Kong, Dept Pharmacol & Pharm, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[4] Univ Hong Kong, Open Lab Chem Biol, Inst Mol Technol Drug Discovery & Synth, Hong Kong, Hong Kong, Peoples R China
[5] Baylor Coll Med, Dept Med, Div Endocrinol Diabet & Metab, Houston, TX 77030 USA
[6] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
[7] Kyungpook Natl Univ, Sch Med, Taegu, South Korea
[8] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China
基金
美国国家卫生研究院;
关键词
Liver injury; Adiponectin; Rosiglitazone; Mitochondria; Uncoupling protein 2; HEPATIC INSULIN SENSITIVITY; PLACEBO-CONTROLLED TRIAL; TYPE-2; DIABETIC-PATIENTS; NONALCOHOLIC STEATOHEPATITIS; POSTTRANSLATIONAL MODIFICATIONS; LACKING ADIPONECTIN; LIPID-METABOLISM; BETA-OXIDATION; MOUSE MODEL; THIAZOLIDINEDIONES;
D O I
10.1016/j.jhep.2010.05.034
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims The beneficial effects of rosiglitazone on non-alcoholic fatty liver disease (NAFLD) have been reported Rosiglitazone treatment stimulates the production of adiponectin an insulin-sensitizing adipokine with hepatoprotective functions The present study aims to investigate the hepatic actions of rosiglitazone in mice without adiponectin Methods NAFLD was induced in wild type and adiponectin knockout (AKO) mice by high-fat diet feeding After rosiglitazone treatment mice were subjected to evaluations on systemic insulin sensitivity lipid profiles hepatic steatosis and inflammation as well as the expression and activity of key molecules Involved in energy metabolism and mitochondrial functions Results Rosightazone treatment prevented hepatic inflammation and reduced the expression of pro-inflammatory cytokines in livers of wild type mice In contrast in livers of AKO mice the same treatment induced severe hepatomegaly and microvesicular hepatosteatosis and caused abnormal accumulation of fatty acyl CoA glycogen and their intermediate metabolites Compared to wild type littermates the anti-inflammatory and the mitochondria-stimulatory activity of rosiglitazone were largely attenuated in AKO mice Replenishment with either adiponectin or uncoupling protein 2 (UCP2) significantly reduced fatty acyl CoA accumulation and increased mitochondrial activities in livers of rosiglitazone-treated AKO mice In addition adiponectin but not UCP2 promoted the activation of glycogen synthase kinase 3beta (GSK3beta) a key molecule Involved in regulating glycogen homeostasis Conclusions Rosiglitazone elicits its protective functions against NAFLD largely through the induction of adiponectin which prevents mitochondria stresses by promoting GSK3beta activation and UCP2 upregulation two pathways coordinating the glucose and lipid metabolism in liver (C) 2010 European Association for the Study of the Liver Published by Elsevier B V All rights reserved
引用
收藏
页码:1108 / 1116
页数:9
相关论文
共 49 条
  • [1] Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
    Aithal, Guruprasad P.
    Thomas, James A.
    Kaye, Philip V.
    Lawson, Adam
    Ryder, Stephen D.
    Spendlove, Ian
    Austin, Andrew S.
    Freeman, Jan G.
    Morgan, Linda
    Weeber, Jonathan
    [J]. GASTROENTEROLOGY, 2008, 135 (04) : 1176 - 1184
  • [2] Al-Salman J, 2000, ANN INTERN MED, V132, P121, DOI 10.7326/0003-4819-132-2-200001180-00006
  • [3] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [4] [Anonymous], HEPATOLOGY
  • [5] Thiazolidinediones for the Treatment in NASH Sustained Benefit After Drug Discontinuation?
    Argo, Curtis K.
    Iezzoni, Julia C.
    Al-Osaimi, Abdullah M. S.
    Caldwell, Stephen H.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2009, 43 (06) : 565 - 568
  • [6] Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
    Bajaj, M
    Suraamornkul, S
    Piper, P
    Hardies, LJ
    Glass, L
    Cersosimo, E
    Pratipanawatr, T
    Miyazaki, Y
    Defronzo, RA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) : 200 - 206
  • [7] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Belfort, Renata
    Harrison, Stephen A.
    Brown, Kenneth
    Darland, Celia
    Finch, Joan
    Hardies, Jean
    Balas, Bogdan
    Gastaldelli, Amalia
    Tio, Fermin
    Pulcini, Joseph
    Berria, Rachele
    Ma, Jennie Z.
    Dwivedi, Sunil
    Havranek, Russell
    Fincke, Chris
    DeFronzo, Ralph
    Bannayan, George A.
    Schenker, Steven
    Cusi, Kenneth
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2297 - 2307
  • [8] ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism
    Berg, AH
    Combs, TP
    Scherer, PE
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (02) : 84 - 89
  • [9] Recent findings concerning thiazolidinediones in the treatment of diabetes
    Boden, G
    Zhang, M
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (03) : 243 - 250
  • [10] Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver:: insights from models of obesity and type 2 diabetes
    Boelsterli, UA
    Bedoucha, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 63 (01) : 1 - 10